Governmental or Regulatory Activity
Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire
Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Federal Judge Blocks NIH Grant Caps as HHS Appeals Ruling
NIH, HHS, research funding, grant caps, indirect costs, federal judge, permanent injunction, Trump administration, medical research, Administrative Procedure Act, legal appeal, U.S. healthcare policy.
IRA round 2 begins as drugmakers sign on to price negotiation process with CMS
Myasthenic Syndromes, Congenital, Mediation, Prices, Medicare, Ira (eukaryote), drugmakers
Six Payer Trends Shaping Market Access in 2025
Market, trends qualifier, Access, Enrollment, 2025, payer, Shapes, payers, Artificial Intelligence
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
In confirmation hearing, FDA nominee Martin Makary talks drug reviews, vaccines, ethics and more
United States Food and Drug Administration, Makary, Vaccines, Ethics, Advisory Committees
Makary Sails Through Senate Confirmation Hearing for FDA Commissioner
Martin Makary, FDA, Senate confirmation hearing, vaccine advisory committee, drug reviews, ethics, staffing changes
Drug Pricing and the Uncertain Future of the IRA Under Trump
IRA, Transplant Registry Unified Management Program, drug price, Medicare, Mediation, repeal, Changing, Uncertainty, Prices